Literature DB >> 20483575

Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in Idiopathic Pulmonary Fibrosis (IPF).

Katerina M Antoniou1, Helen A Papadaki, Giannoula Soufla, Maria Christina Kastrinaki, Athina Damianaki, Helen Koutala, Demetrios A Spandidos, Nikolaos M Siafakas.   

Abstract

BACKGROUND: Experimental data have provided evidence that progenitor cells of bone marrow (BM) origin may play a role in the fibrogenic process of the lung.
OBJECTIVE: To probe the possible involvement of BM mesenchymal stem cells (MSCs) in the pathophysiology of Idiopathic Pulmonary Fibrosis (IPF) by investigating the molecular profile of these cells.
DESIGN: BM MSCs were studied in 10 IPF patients and 10 healthy controls. MSCs were identified by their immunophenotypic characteristics and their potential to differentiate towards adipocytes/osteocytes/chondrocytes. We evaluated the mRNA expression of genes involved in the lung injury of IPF, namely the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), transforming growth factor beta-1 (TGF-beta1) and the axis stromal-cell-derived factor-1 (SDF-1)/CXCR4 in BM MSCs using quantitative RT-PCR.
RESULTS: The BM MSCs of IPF patients displayed normal immunophenotypic characteristics and differentiation potential. No statistically significant difference was found between patients and controls in VEGF and FGF mRNA expression. TGF-beta1 was not expressed in either patients or controls. A significant increase in SDF-1-TR1 and CXCR4 mRNA expression was detected in IPF patients (1.6 x 10(25) +/- 1.2 x 10(25) and 3.1 x 10(7) +/- 3.1 x 10(7), respectively) compared to controls (0.32 x 10(25) +/- 0.07 x 10(25) and 1.67 x 10(7) +/- 0.30 x 10(7), respectively) (p = 0.001 and p = 0.001, respectively) whereas SDF-1 levels in MSC supernatants were similar in patients and controls.
CONCLUSIONS: The increased CXCR4 expression by patient MSCs suggests that the BM is probably implicated in the pathophysiology of IPF by mobilizing MSCs in response to or preceding lung injury. The potential role of BM MSCs in IPF is another interesting field for further investigation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483575     DOI: 10.1016/j.rmed.2010.04.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  17 in total

1.  Transforming growth factor-β1 promotes homing of bone marrow mesenchymal stem cells in renal ischemia-reperfusion injury.

Authors:  Xiaoyun Si; Ximing Liu; Jingjing Li; Xiaoyan Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP.

Authors:  Katerina M Antoniou; George A Margaritopoulos; Athanasia Proklou; Konstantinos Karagiannis; Ismini Lasithiotaki; Giannoula Soufla; Maria Christina Kastrinaki; Demetrios A Spandidos; Helen A Papadaki; Nikos M Siafakas
Journal:  J Inflamm (Lond)       Date:  2012-07-02       Impact factor: 4.981

3.  Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts.

Authors:  Na Tang; Yanxia Zhao; Ruopeng Feng; Yinan Liu; Shuling Wang; Wanguo Wei; Qiang Ding; Michael Songzhu An; Jinhua Wen; Lingsong Li
Journal:  J Cell Mol Med       Date:  2013-11-19       Impact factor: 5.310

Review 4.  The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.

Authors:  Ana Camelo; Rebecca Dunmore; Matthew A Sleeman; Deborah L Clarke
Journal:  Front Pharmacol       Date:  2014-01-10       Impact factor: 5.810

Review 5.  Cell-based therapy in lung regenerative medicine.

Authors:  Jibing Yang; Zhenquan Jia
Journal:  Regen Med Res       Date:  2014-04-11

6.  Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial.

Authors:  Arantza Campo; José María González-Ruiz; Enrique Andreu; Ana B Alcaide; María M Ocón; Juan De-Torres; Jesús Pueyo; Rosa Cordovilla; Eva Villaron; Fermín Sanchez-Guijo; Miguel Barrueco; Jorge Nuñez-Córdoba; Felipe Prósper; Javier J Zulueta
Journal:  ERJ Open Res       Date:  2021-06-28

Review 7.  Stem Cells and Regenerative Medicine: Myth or Reality of the 21th Century.

Authors:  J-F Stoltz; N de Isla; Y P Li; D Bensoussan; L Zhang; C Huselstein; Y Chen; V Decot; J Magdalou; N Li; L Reppel; Y He
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

8.  Amniotic fluid stem cells inhibit the progression of bleomycin-induced pulmonary fibrosis via CCL2 modulation in bronchoalveolar lavage.

Authors:  Orquidea Garcia; Gianni Carraro; Gianluca Turcatel; Marisa Hall; Sargis Sedrakyan; Tyler Roche; Sue Buckley; Barbara Driscoll; Laura Perin; David Warburton
Journal:  PLoS One       Date:  2013-08-13       Impact factor: 3.240

9.  Activated Wnt signaling induces myofibroblast differentiation of mesenchymal stem cells, contributing to pulmonary fibrosis.

Authors:  Zhaorui Sun; Cong Wang; Chaowen Shi; Fangfang Sun; Xiaomeng Xu; Weiping Qian; Shinan Nie; Xiaodong Han
Journal:  Int J Mol Med       Date:  2014-02-25       Impact factor: 4.101

Review 10.  Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy.

Authors:  George A Margaritopoulos; Eirini Vasarmidi; Katerina M Antoniou
Journal:  Core Evid       Date:  2016-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.